Financial Data and Key Metrics Changes - Aytu BioScience reported a record net revenue of over $15.1 million for Q2 2021, representing a 377% increase compared to the same quarter last year and a 12% sequential growth over Q1 2021 [4][8] - The adjusted EBITDA loss was approximately $1.8 million, an improvement of over $1 million compared to the adjusted EBITDA loss of $2.9 million in Q2 2020 [8][11] - Gross profit for Q2 was $9.1 million, with a gross profit margin of approximately 60%, down from 81% in the same quarter last year due to lower margins from COVID-19 test kit sales [9][10] Business Line Data and Key Metrics Changes - The consumer health division achieved an all-time revenue high of $7.9 million, while the Rx division generated $7.2 million, a 25% increase from the previous quarter [6][14] - The pediatric segment, particularly Poly-Vi-Flor, contributed to Rx revenue growth, alongside revenue from COVID-19 test kits [15][19] Market Data and Key Metrics Changes - The COVID-19 testing market remains robust, with Aytu having successfully sourced an antigen test that has seen strong market acceptance [27][28] - The company anticipates continued demand for antibody testing as the market evolves [28] Company Strategy and Development Direction - Aytu is focused on integrating the Innovus Consumer Health business and the Cerecor pediatric assets, while also pursuing additional growth drivers and acquisitions [5][18] - The planned merger with Neos Therapeutics is expected to close by Q2 2021, creating a specialty pharmaceutical company with pro forma annual revenue exceeding $100 million [5][18] - The merger is anticipated to yield annual cost synergies of approximately $15 million starting in FY '22 [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's strategic transformation and the potential of the Healight technology in treating respiratory diseases [17][20] - The focus remains on top-line growth and achieving profitability, with a strong cash balance of over $62 million to support future initiatives [7][12] Other Important Information - Aytu completed a $28.75 million public offering, which will help pay down a substantial portion of Neos' debt upon merger closing [12] - The company ended the quarter with total assets of $167 million and equity of $113 million [12] Q&A Session Summary Question: Growth expectations for the pediatric side of the business - Management expects continued growth in the pediatric segment, leveraging experience from the Cerecor acquisition and the upcoming Neos transaction [22][24] Question: Contribution of COVID-19 business to overall revenues - The COVID-19 testing business has been meaningful, with management noting the importance of being opportunistic in this market while focusing on broader growth [25][27][28] Question: Future expectations for gross margins - Management indicated that gross margins are expected to stabilize between 70% to 80%, depending on the contributions from the Rx and consumer health segments [31][32]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38247 AYTU BIOSCIENCE, INC. (www.aytubio.com) Delaware 47-0883144 (State or other jurisdiction of incorporation or organization) (IRS Emp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 333-146542 AYTU BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) 47-0883144 | --- | --- | |---------------------------|------------------------------------ ...

Aytu BioScience, Inc. (NASDAQ:AYTU) Q3 2020 Results Earnings Conference Call May 14, 2020 4:30 PM ET Company Participants Joshua Disbrow - Chairman & CEO David Green - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good afternoon, and thank you for joining us at the Aytu BioScience Third Quarter Fiscal 2020 Business Update Call for the quarter ending March 31, 2020. With me this afternoon are Aytu's Chairman and Chief Executive Officer, Josh Disbrow; and Chief Financial Officer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share AYTU The NASDAQ Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share AYTU The NASDAQ Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss ...

Aytu BioScience, Inc. (NASDAQ:AYTU) Q2 2020 Earnings Conference Call February 13, 2020 4:30 PM ET Company Participants Josh Disbrow – Chairman and Chief Executive Officer Dave Green – Chief Financial Officer Conference Call Participants Carl Byrnes – Northland Securities Jeffrey Cohen – Ladenburg Thalmann Operator Good afternoon and thank you for joining us for the Aytu BioScience Second Quarter Fiscal 2020 Business Update Call for the Quarter Ended December 31, 2019. With me this afternoon are Aytu's Chair ...